Cryofocus Medtech (Shanghai) Future Growth
Future criteria checks 2/6
Cryofocus Medtech (Shanghai) is forecast to grow earnings and revenue by 68.5% and 46.1% per annum respectively. EPS is expected to grow by 69.2% per annum. Return on equity is forecast to be -13.1% in 3 years.
Key information
68.5%
Earnings growth rate
69.2%
EPS growth rate
| Medical Equipment earnings growth | 34.9% |
| Revenue growth rate | 46.1% |
| Future return on equity | -13.1% |
| Analyst coverage | Low |
| Last updated | 15 Jan 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 591 | N/A | 60 | N/A | 1 |
| 12/31/2025 | 351 | -15 | -28 | 0 | 2 |
| 12/31/2024 | 171 | -68 | -87 | -64 | 2 |
| 12/31/2023 | 41 | -97 | -111 | -96 | N/A |
| 9/30/2023 | 38 | -105 | -116 | -106 | N/A |
| 6/30/2023 | 36 | -113 | -122 | -115 | N/A |
| 3/31/2023 | 31 | -113 | -113 | -106 | N/A |
| 12/31/2022 | 27 | -112 | -104 | -97 | N/A |
| 12/31/2021 | 22 | -102 | -75 | -62 | N/A |
| 12/31/2020 | 9 | -137 | -36 | -34 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6922 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6922 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6922 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6922's revenue (46.1% per year) is forecast to grow faster than the Hong Kong market (7.9% per year).
High Growth Revenue: 6922's revenue (46.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6922 is forecast to be unprofitable in 3 years.